Drug Treatment

/Drug Treatment

Deciphera Releases Positive Trial Results for Ripretinib

Deciphera Pharmaceuticals has released positive results from their INVICTUS Phase 3 Clinical Study of Ripretinib in patients with GIST. They have also updated results from the Phase 1 Study. Deciphera shared that "patients treated [...]

By |2019-08-14T09:38:14-04:00August 14th, 2019|Drug Treatment, News, Research|

Blueprint Medicines Announces Next Step for Avaprinitib

Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST Blueprint Medicines announced today that the FDA and the EMA have [...]

By |2019-08-07T13:24:21-04:00August 7th, 2019|Drug Treatment, News|

Examining Kidney Toxicities of Sunitinib and Imatinib in Long-Term GIST Therapy

On September 19, 2016 the Life Raft Group was pleased to have Dr. Benjamin D. Humphreys, Chief of the Division of Nephrology at Washington University in St. Louis School of Medicine, share his knowledge [...]

By |2018-10-30T09:34:18-04:00September 19th, 2016|GIST Education, Gleevec, Sutent, Webcast|

Webcast Provides Perspective on Generic Imatinib

On February 1, 2016, the commercial launch of the generic version of imatinib mesylate (Gleevec), originally for CML (Chronic Myeloid Leukemia), was approved by the FDA and became available for the first time [...]

By |2018-10-30T09:55:00-04:00April 8th, 2016|Generics, GIST Education, Newsletter, Webcast|

Study Finds Adjuvant Systemic Therapy with Imatinib Increasing Over Time

A recent study published in the American Journal of Clinical Oncology found that the use of adjuvant systemic therapy with imatinib for GIST has increased significantly over time, and that patients treated with the [...]

By |2018-10-30T09:55:33-04:00March 15th, 2016|Drug Treatment, News, Survival Strategies|

Generic Imatinib Approved in the US for CML: What does it mean for GIST patients?

Note: The content of this article is current to the time of its posting on February 10, 2016. Please continue to check our site for the latest information on generics. On February 1, 2016, [...]

By |2018-12-17T10:51:32-04:00February 10th, 2016|Drug Treatment, Generics, Gleevec, News, Newsletter|

Recent Posts

Upcoming Events

  1. Blueprint Medicines logo

    Informational Webinar on Avapritinib

    August 20 @ 4:00 PM - 5:00 PM
  2. Dr. Sicklick presents an update on Temozolomide Trial